Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study.
Saved in:
| Title: | Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study. |
|---|---|
| Authors: | Langslet G; Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital 0424, Oslo, Norway., Nyström T; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet 118 83, Stockholm, Sweden., Vistisen D; Clinical Epidemiology, Steno Diabetes Center Copenhagen 2730, Herlev, Denmark.; A/I and Analytics, Novo Nordisk A/S, AI and Analytics, Søborg, Denmark., Carstensen B; Clinical Epidemiology, Steno Diabetes Center Copenhagen 2730, Herlev, Denmark., Grip ET; Real World Data and Data Analytics, Quantify Research 11221, Stockholm, Sweden.; Department of Medicine, Karolinska Institutet 141 57, Huddinge, Sweden., Casajust P; Real-World Data and Data Analytics, TFS HealthScience 08007, Barcelona, Spain., Tskhvarashvili G; Global Database Studies, Real World Solutions, IQVIA 10119, Tallinn, Estonia., Hoti F; Global Database Studies, Real World Solutions, IQVIA 02130, Espoo, Finland., Klement R; Global Database Studies, Real World Solutions, IQVIA, 51013, Tartu, Estonia., Karlsdotter K; Market Access, Boehringer Ingelheim Pharmaceuticals 12032, Stockholm, Sweden., Tuovinen M; Global Medical Affairs, Boehringer Ingelheim Pharmaceuticals 00180, Helsinki, Finland., Ofstad AP; Type 2 Diabetes and Metabolism, Medical Department, Boehringer Ingelheim 1383, Oslo, KS, Norway.; Department of Medicine, Oslo Diabetes Research Center 0424, Oslo, Norway., Lajer M; Global Integrated Evidence, Boehringer Ingelheim Pharmaceuticals 2100, Copenhagen, Denmark., Shay C; Global Integrated Evidence, Boehringer Ingelheim Pharmaceuticals, Inc. 06877, Ridgefield, Connecticut, USA., Koeneman L; Diabetes Global Medical Affairs, Lilly Deutschland GmbH 61352, Bad Homburg, Germany., Farsani SF; Global Integrated Evidence, Boehringer Ingelheim International GmbH 55216, Ingelheim, Germany., Niskanen L; Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital 15850, Lahti, Finland.; Institute of Clinical Medicine, University of Eastern Finland 70210, Kuopio, Finland., Halvorsen S; Department of Cardiology, Oslo University Hospital Ullevål 0450, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo 0372, Oslo, Norway. |
| Source: | Journal of diabetes research [J Diabetes Res] 2024 Oct 12; Vol. 2024, pp. 6142211. Date of Electronic Publication: 2024 Oct 12 (Print Publication: 2024). |
| Publication Type: | Journal Article; Comparative Study; Multicenter Study |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101605237 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6753 (Electronic) NLM ISO Abbreviation: J Diabetes Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39430801 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Langslet+G%22">Langslet G</searchLink>; Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital 0424, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Nyström+T%22">Nyström T</searchLink>; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet 118 83, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Vistisen+D%22">Vistisen D</searchLink>; Clinical Epidemiology, Steno Diabetes Center Copenhagen 2730, Herlev, Denmark.; A/I and Analytics, Novo Nordisk A/S, AI and Analytics, Søborg, Denmark.<br /><searchLink fieldCode="AU" term="%22Carstensen+B%22">Carstensen B</searchLink>; Clinical Epidemiology, Steno Diabetes Center Copenhagen 2730, Herlev, Denmark.<br /><searchLink fieldCode="AU" term="%22Grip+ET%22">Grip ET</searchLink>; Real World Data and Data Analytics, Quantify Research 11221, Stockholm, Sweden.; Department of Medicine, Karolinska Institutet 141 57, Huddinge, Sweden.<br /><searchLink fieldCode="AU" term="%22Casajust+P%22">Casajust P</searchLink>; Real-World Data and Data Analytics, TFS HealthScience 08007, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Tskhvarashvili+G%22">Tskhvarashvili G</searchLink>; Global Database Studies, Real World Solutions, IQVIA 10119, Tallinn, Estonia.<br /><searchLink fieldCode="AU" term="%22Hoti+F%22">Hoti F</searchLink>; Global Database Studies, Real World Solutions, IQVIA 02130, Espoo, Finland.<br /><searchLink fieldCode="AU" term="%22Klement+R%22">Klement R</searchLink>; Global Database Studies, Real World Solutions, IQVIA, 51013, Tartu, Estonia.<br /><searchLink fieldCode="AU" term="%22Karlsdotter+K%22">Karlsdotter K</searchLink>; Market Access, Boehringer Ingelheim Pharmaceuticals 12032, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Tuovinen+M%22">Tuovinen M</searchLink>; Global Medical Affairs, Boehringer Ingelheim Pharmaceuticals 00180, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Ofstad+AP%22">Ofstad AP</searchLink>; Type 2 Diabetes and Metabolism, Medical Department, Boehringer Ingelheim 1383, Oslo, KS, Norway.; Department of Medicine, Oslo Diabetes Research Center 0424, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Lajer+M%22">Lajer M</searchLink>; Global Integrated Evidence, Boehringer Ingelheim Pharmaceuticals 2100, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Shay+C%22">Shay C</searchLink>; Global Integrated Evidence, Boehringer Ingelheim Pharmaceuticals, Inc. 06877, Ridgefield, Connecticut, USA.<br /><searchLink fieldCode="AU" term="%22Koeneman+L%22">Koeneman L</searchLink>; Diabetes Global Medical Affairs, Lilly Deutschland GmbH 61352, Bad Homburg, Germany.<br /><searchLink fieldCode="AU" term="%22Farsani+SF%22">Farsani SF</searchLink>; Global Integrated Evidence, Boehringer Ingelheim International GmbH 55216, Ingelheim, Germany.<br /><searchLink fieldCode="AU" term="%22Niskanen+L%22">Niskanen L</searchLink>; Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital 15850, Lahti, Finland.; Institute of Clinical Medicine, University of Eastern Finland 70210, Kuopio, Finland.<br /><searchLink fieldCode="AU" term="%22Halvorsen+S%22">Halvorsen S</searchLink>; Department of Cardiology, Oslo University Hospital Ullevål 0450, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo 0372, Oslo, Norway. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101605237%22">Journal of diabetes research</searchLink> [J Diabetes Res] 2024 Oct 12; Vol. 2024, pp. 6142211. <i>Date of Electronic Publication: </i>2024 Oct 12 (<i>Print Publication: </i>2024). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Comparative Study; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101605237 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2314-6753 (Electronic) <i>NLM ISO Abbreviation: </i>J Diabetes Res <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39430801 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1155/2024/6142211 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 6142211 Titles: – TitleFull: Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Langslet G – PersonEntity: Name: NameFull: Nyström T – PersonEntity: Name: NameFull: Vistisen D – PersonEntity: Name: NameFull: Carstensen B – PersonEntity: Name: NameFull: Grip ET – PersonEntity: Name: NameFull: Casajust P – PersonEntity: Name: NameFull: Tskhvarashvili G – PersonEntity: Name: NameFull: Hoti F – PersonEntity: Name: NameFull: Klement R – PersonEntity: Name: NameFull: Karlsdotter K – PersonEntity: Name: NameFull: Tuovinen M – PersonEntity: Name: NameFull: Ofstad AP – PersonEntity: Name: NameFull: Lajer M – PersonEntity: Name: NameFull: Shay C – PersonEntity: Name: NameFull: Koeneman L – PersonEntity: Name: NameFull: Farsani SF – PersonEntity: Name: NameFull: Niskanen L – PersonEntity: Name: NameFull: Halvorsen S IsPartOfRelationships: – BibEntity: Dates: – D: 12 M: 10 Text: 2024 Oct 12 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2314-6753 Numbering: – Type: volume Value: 2024 Titles: – TitleFull: Journal of diabetes research Type: main |
| ResultId | 1 |
